These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 37528211)

  • 1. Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
    Fang S; Zhang S; Zhang C; Wang L
    Paediatr Drugs; 2023 Sep; 25(5):499-513. PubMed ID: 37528211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review.
    Fang S; Song Y; Zhang C; Wang L
    BMC Pediatr; 2022 Apr; 22(1):175. PubMed ID: 35379216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal transplantation for treatment of inflammatory bowel disease.
    Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
    Ghosh S; Feagan BG; Ott E; Gasink C; Godwin B; Marano C; Miao Y; Ma T; Loftus EV; Sandborn WJ; Danese S; Abreu MT; Sands BE
    J Crohns Colitis; 2024 Aug; 18(7):1091-1101. PubMed ID: 38310565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.
    Lim CT; Tay SW; Elangovan S; Ong WC; Lim GH; Salazar E; Chan WPW; Tan MTK
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1544-1553. PubMed ID: 38680014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
    Sandborn WJ; Feagan BG; Danese S; O'Brien CD; Ott E; Marano C; Baker T; Zhou Y; Volger S; Tikhonov I; Gasink C; Sands BE; Ghosh S
    Inflamm Bowel Dis; 2021 Jun; 27(7):994-1007. PubMed ID: 32964215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Yang H; Li B; Guo Q; Tang J; Peng B; Ding N; Li M; Yang Q; Huang Z; Diao N; Zhu X; Deng J; Guo H; Hu P; Chao K; Gao X
    Aliment Pharmacol Ther; 2022 Apr; 55(7):764-777. PubMed ID: 35141914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
    Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
    J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
    Yang C; Singh P; Singh H; Le ML; El-Matary W
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1079-93. PubMed ID: 25858208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease.
    Limketkai BN; Iheozor-Ejiofor Z; Gjuladin-Hellon T; Parian A; Matarese LE; Bracewell K; MacDonald JK; Gordon M; Mullin GE
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012839. PubMed ID: 30736095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
    Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
    Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose naltrexone for induction of remission in Crohn's disease.
    Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.